HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Firm's Discontinued Hair Volume Claims Keep Growing Back; NAD Alerts FTC

This article was originally published in The Rose Sheet

Executive Summary

New Nordic's seeming refusal to dispense with hair-growth claims in ads for its Hair Volume supplement, despite repeated promises to the National Advertising Division, has resulted in a referral to the Federal Trade Commission.

You may also be interested in...



UK Ad Authority Gives Caffeinated Shampoo Maker A Wakeup Call

Dr. Kurt Wolff’s study data for Alpecin Caffeine Shampoo is insufficient to support statements about hair-loss reduction, according to the Advertising Standards Authority’s March 28 ruling.

C&D Viviscal Deal Adds Supplement, Hair Care And E-commerce Heft

The $160.4m deal reported with Lifes2Good expands the firm's play in the subscription sales space it entered with the Toppik Hair Building Fibers brand.

P&G’s NIOXIN Shows How To Address Hair Loss Without An FDA Warning

With FDA scrutinizing the marketplace for cosmetics promoted as drugs, and a clear cautionary statement from the agency about topical products marketed as hair growers or hair-loss preventers, beauty firms have little choice but to incorporate approved OTC drug ingredients in such products. P&G’s professional hair-care brand NIOXIN has done just that with its new Advanced Thinning range featuring minoxidil.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019651

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel